Cargando…
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for...
Autores principales: | Pearson, James A, McKinney, Eoin F, Walker, Lucy S K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826223/ https://www.ncbi.nlm.nih.gov/pubmed/35156097 http://dx.doi.org/10.1093/immadv/ltab024 |
Ejemplares similares
-
Correction to: 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
Publicado: (2022) -
Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021) -
A Look Into the Next Century After 100 Years of Insulin
por: Gupta, Sonal, et al.
Publicado: (2022) -
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
por: Qiu, Yingqi, et al.
Publicado: (2021) -
The Next Frontiers
por: Porcino, Antony
Publicado: (2013)